Stereotactic Body Radiation Therapy and Primary Tumor Control in NSCLC
Posted: Wednesday, December 1, 2021
According to research presented at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 175), the use of stereotactic body radiation therapy (SBRT) boosts may be an effective and well-tolerated means of targeting primary tumors for patients with unresectable, locally advanced, non–small cell lung cancer. This treatment has been shown to result in increased primary tumor control among patients with early-stage disease.
“Through the use of one CT simulation data set, accurate calculation of the planned dose through the two sequentially delivered plans is achievable,” concluded Terence M. Williams, MD, PhD, of City of Hope National Medical Center in California, and colleagues.
The phase II trial included 21 patients, 16 of whom received 6 Gy x 2 SBRT boost and 5 of whom received 8 Gy x 2 SBRT boost. A total of 6 patients underwent consolidation durvalumab, and 18 received carboplatin/paclitaxel. Prior to treatment, the median baseline primary tumor size was 5 cm.
Median survival was 37.8 months. At a follow-up of 2 years, the disease-free and overall survival rates were 46.1% and 50.3%, respectively. The overall response rate was 72.7% at 3 months and 80.0% at 6 months. At a follow-up of 1 year, the primary tumor control rate was 100%; at 2 years, it was 92.3%.
Fatigue, neutropenia, leukopenia, lymphopenia, anemia, pneumonitis, fibrosis, dyspnea, and esophagitis were common toxicities. Grade 4 treatment-related adverse events included lymphopenia (n = 3), neutropenia (n = 1), and leukopenia (n = 1). No grade 5 treatment-related adverse events were reported.
Disclosure: For full disclosures of the study authors, visit astro.org.
